nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Ifosfamide—testicular cancer	0.155	0.428	CbGbCtD
Fosamprenavir—CYP3A4—Vinblastine—testicular cancer	0.0823	0.227	CbGbCtD
Fosamprenavir—CYP3A4—Etoposide—testicular cancer	0.0741	0.205	CbGbCtD
Fosamprenavir—CYP3A4—Doxorubicin—testicular cancer	0.0506	0.14	CbGbCtD
Fosamprenavir—Erythema multiforme—Dactinomycin—testicular cancer	0.00355	0.00557	CcSEcCtD
Fosamprenavir—Anorexia—Chlorambucil—testicular cancer	0.00352	0.00552	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00346	0.00543	CcSEcCtD
Fosamprenavir—Haemoglobin—Ifosfamide—testicular cancer	0.00346	0.00542	CcSEcCtD
Fosamprenavir—Haemorrhage—Ifosfamide—testicular cancer	0.00344	0.00539	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Ifosfamide—testicular cancer	0.0034	0.00533	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Ifosfamide—testicular cancer	0.00338	0.0053	CcSEcCtD
Fosamprenavir—Urethral disorder—Ifosfamide—testicular cancer	0.00337	0.00529	CcSEcCtD
Fosamprenavir—Inflammation—Methotrexate—testicular cancer	0.00334	0.00524	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Cisplatin—testicular cancer	0.00326	0.00511	CcSEcCtD
Fosamprenavir—Erythema multiforme—Ifosfamide—testicular cancer	0.00325	0.0051	CcSEcCtD
Fosamprenavir—Myocardial infarction—Cisplatin—testicular cancer	0.00324	0.00508	CcSEcCtD
Fosamprenavir—Anorexia—Vinblastine—testicular cancer	0.00323	0.00506	CcSEcCtD
Fosamprenavir—Decreased appetite—Chlorambucil—testicular cancer	0.00321	0.00504	CcSEcCtD
Fosamprenavir—Cardiac disorder—Ifosfamide—testicular cancer	0.00319	0.00501	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00319	0.005	CcSEcCtD
Fosamprenavir—Fatigue—Chlorambucil—testicular cancer	0.00319	0.00499	CcSEcCtD
Fosamprenavir—Neutropenia—Etoposide—testicular cancer	0.00317	0.00498	CcSEcCtD
Fosamprenavir—Inflammation—Epirubicin—testicular cancer	0.00313	0.0049	CcSEcCtD
Fosamprenavir—Immune system disorder—Ifosfamide—testicular cancer	0.00311	0.00487	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00302	0.00474	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.003	0.0047	CcSEcCtD
Fosamprenavir—Malnutrition—Ifosfamide—testicular cancer	0.003	0.0047	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Etoposide—testicular cancer	0.00298	0.00468	CcSEcCtD
Fosamprenavir—Myalgia—Bleomycin—testicular cancer	0.00298	0.00468	CcSEcCtD
Fosamprenavir—Myocardial infarction—Etoposide—testicular cancer	0.00297	0.00465	CcSEcCtD
Fosamprenavir—Decreased appetite—Vinblastine—testicular cancer	0.00294	0.00461	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Cisplatin—testicular cancer	0.00293	0.00459	CcSEcCtD
Fosamprenavir—Abdominal pain—Chlorambucil—testicular cancer	0.00292	0.00458	CcSEcCtD
Fosamprenavir—Body temperature increased—Chlorambucil—testicular cancer	0.00292	0.00458	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Cisplatin—testicular cancer	0.00291	0.00457	CcSEcCtD
Fosamprenavir—Urethral disorder—Cisplatin—testicular cancer	0.00291	0.00456	CcSEcCtD
Fosamprenavir—Inflammation—Doxorubicin—testicular cancer	0.00289	0.00454	CcSEcCtD
Fosamprenavir—Myalgia—Dactinomycin—testicular cancer	0.00278	0.00436	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Vinblastine—testicular cancer	0.00277	0.00434	CcSEcCtD
Fosamprenavir—Cardiac disorder—Cisplatin—testicular cancer	0.00275	0.00432	CcSEcCtD
Fosamprenavir—Angioedema—Ifosfamide—testicular cancer	0.00274	0.00429	CcSEcCtD
Fosamprenavir—Anorexia—Bleomycin—testicular cancer	0.00273	0.00427	CcSEcCtD
Fosamprenavir—Hypersensitivity—Chlorambucil—testicular cancer	0.00272	0.00427	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Methotrexate—testicular cancer	0.00271	0.00424	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Etoposide—testicular cancer	0.00268	0.00421	CcSEcCtD
Fosamprenavir—Immune system disorder—Cisplatin—testicular cancer	0.00268	0.0042	CcSEcCtD
Fosamprenavir—Abdominal pain—Vinblastine—testicular cancer	0.00268	0.0042	CcSEcCtD
Fosamprenavir—Urethral disorder—Etoposide—testicular cancer	0.00266	0.00418	CcSEcCtD
Fosamprenavir—Asthenia—Chlorambucil—testicular cancer	0.00265	0.00416	CcSEcCtD
Fosamprenavir—Pruritus—Chlorambucil—testicular cancer	0.00261	0.0041	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00261	0.00408	CcSEcCtD
Fosamprenavir—Malnutrition—Cisplatin—testicular cancer	0.00258	0.00405	CcSEcCtD
Fosamprenavir—Erythema multiforme—Etoposide—testicular cancer	0.00257	0.00403	CcSEcCtD
Fosamprenavir—Myalgia—Ifosfamide—testicular cancer	0.00255	0.004	CcSEcCtD
Fosamprenavir—Flatulence—Cisplatin—testicular cancer	0.00254	0.00399	CcSEcCtD
Fosamprenavir—Anorexia—Dactinomycin—testicular cancer	0.00254	0.00399	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00253	0.00397	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Epirubicin—testicular cancer	0.00253	0.00397	CcSEcCtD
Fosamprenavir—Diarrhoea—Chlorambucil—testicular cancer	0.00253	0.00396	CcSEcCtD
Fosamprenavir—Cardiac disorder—Etoposide—testicular cancer	0.00252	0.00395	CcSEcCtD
Fosamprenavir—Hypersensitivity—Vinblastine—testicular cancer	0.0025	0.00391	CcSEcCtD
Fosamprenavir—Decreased appetite—Bleomycin—testicular cancer	0.00249	0.0039	CcSEcCtD
Fosamprenavir—Immune system disorder—Etoposide—testicular cancer	0.00245	0.00385	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00243	0.00381	CcSEcCtD
Fosamprenavir—Asthenia—Vinblastine—testicular cancer	0.00243	0.00381	CcSEcCtD
Fosamprenavir—Nervous system disorder—Ifosfamide—testicular cancer	0.0024	0.00376	CcSEcCtD
Fosamprenavir—Skin disorder—Ifosfamide—testicular cancer	0.00237	0.00372	CcSEcCtD
Fosamprenavir—Vomiting—Chlorambucil—testicular cancer	0.00235	0.00368	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Doxorubicin—testicular cancer	0.00234	0.00367	CcSEcCtD
Fosamprenavir—Anorexia—Ifosfamide—testicular cancer	0.00233	0.00365	CcSEcCtD
Fosamprenavir—Decreased appetite—Dactinomycin—testicular cancer	0.00232	0.00364	CcSEcCtD
Fosamprenavir—Diarrhoea—Vinblastine—testicular cancer	0.00232	0.00363	CcSEcCtD
Fosamprenavir—Fatigue—Dactinomycin—testicular cancer	0.0023	0.00361	CcSEcCtD
Fosamprenavir—Body temperature increased—Bleomycin—testicular cancer	0.00226	0.00354	CcSEcCtD
Fosamprenavir—Dizziness—Vinblastine—testicular cancer	0.00224	0.00351	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00223	0.00349	CcSEcCtD
Fosamprenavir—Myalgia—Cisplatin—testicular cancer	0.0022	0.00345	CcSEcCtD
Fosamprenavir—Nausea—Chlorambucil—testicular cancer	0.0022	0.00344	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00218	0.00342	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00218	0.00342	CcSEcCtD
Fosamprenavir—Vomiting—Vinblastine—testicular cancer	0.00215	0.00338	CcSEcCtD
Fosamprenavir—Decreased appetite—Ifosfamide—testicular cancer	0.00212	0.00333	CcSEcCtD
Fosamprenavir—Headache—Vinblastine—testicular cancer	0.00212	0.00333	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00211	0.00331	CcSEcCtD
Fosamprenavir—Abdominal pain—Dactinomycin—testicular cancer	0.00211	0.00331	CcSEcCtD
Fosamprenavir—Body temperature increased—Dactinomycin—testicular cancer	0.00211	0.00331	CcSEcCtD
Fosamprenavir—Fatigue—Ifosfamide—testicular cancer	0.00211	0.0033	CcSEcCtD
Fosamprenavir—Hypersensitivity—Bleomycin—testicular cancer	0.00211	0.0033	CcSEcCtD
Fosamprenavir—Nervous system disorder—Cisplatin—testicular cancer	0.00207	0.00324	CcSEcCtD
Fosamprenavir—Asthenia—Bleomycin—testicular cancer	0.00205	0.00322	CcSEcCtD
Fosamprenavir—Skin disorder—Cisplatin—testicular cancer	0.00205	0.00321	CcSEcCtD
Fosamprenavir—Pruritus—Bleomycin—testicular cancer	0.00202	0.00317	CcSEcCtD
Fosamprenavir—Nausea—Vinblastine—testicular cancer	0.00201	0.00315	CcSEcCtD
Fosamprenavir—Anorexia—Cisplatin—testicular cancer	0.00201	0.00315	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.002	0.00314	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Ifosfamide—testicular cancer	0.002	0.00313	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.00198	0.00311	CcSEcCtD
Fosamprenavir—Hypersensitivity—Dactinomycin—testicular cancer	0.00197	0.00308	CcSEcCtD
Fosamprenavir—Gastritis—Epirubicin—testicular cancer	0.00195	0.00305	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00194	0.00304	CcSEcCtD
Fosamprenavir—Abdominal pain—Ifosfamide—testicular cancer	0.00193	0.00303	CcSEcCtD
Fosamprenavir—Body temperature increased—Ifosfamide—testicular cancer	0.00193	0.00303	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00192	0.00301	CcSEcCtD
Fosamprenavir—Asthenia—Dactinomycin—testicular cancer	0.00191	0.003	CcSEcCtD
Fosamprenavir—Neutropenia—Methotrexate—testicular cancer	0.0019	0.00298	CcSEcCtD
Fosamprenavir—Skin disorder—Etoposide—testicular cancer	0.00188	0.00294	CcSEcCtD
Fosamprenavir—Anorexia—Etoposide—testicular cancer	0.00184	0.00288	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.00183	0.00288	CcSEcCtD
Fosamprenavir—Decreased appetite—Cisplatin—testicular cancer	0.00183	0.00287	CcSEcCtD
Fosamprenavir—Diarrhoea—Dactinomycin—testicular cancer	0.00183	0.00286	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00182	0.00285	CcSEcCtD
Fosamprenavir—Vomiting—Bleomycin—testicular cancer	0.00182	0.00285	CcSEcCtD
Fosamprenavir—Rash—Bleomycin—testicular cancer	0.0018	0.00283	CcSEcCtD
Fosamprenavir—Gastritis—Doxorubicin—testicular cancer	0.0018	0.00283	CcSEcCtD
Fosamprenavir—Dermatitis—Bleomycin—testicular cancer	0.0018	0.00282	CcSEcCtD
Fosamprenavir—Hypersensitivity—Ifosfamide—testicular cancer	0.0018	0.00282	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.0018	0.00282	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.0018	0.00282	CcSEcCtD
Fosamprenavir—Neutropenia—Epirubicin—testicular cancer	0.00178	0.00279	CcSEcCtD
Fosamprenavir—Asthenia—Ifosfamide—testicular cancer	0.00175	0.00275	CcSEcCtD
Fosamprenavir—Pruritus—Ifosfamide—testicular cancer	0.00173	0.00271	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Epirubicin—testicular cancer	0.00172	0.00269	CcSEcCtD
Fosamprenavir—Nausea—Bleomycin—testicular cancer	0.0017	0.00266	CcSEcCtD
Fosamprenavir—Vomiting—Dactinomycin—testicular cancer	0.0017	0.00266	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00168	0.00264	CcSEcCtD
Fosamprenavir—Rash—Dactinomycin—testicular cancer	0.00168	0.00264	CcSEcCtD
Fosamprenavir—Decreased appetite—Etoposide—testicular cancer	0.00168	0.00263	CcSEcCtD
Fosamprenavir—Diarrhoea—Ifosfamide—testicular cancer	0.00167	0.00262	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Etoposide—testicular cancer	0.00167	0.00261	CcSEcCtD
Fosamprenavir—Body temperature increased—Cisplatin—testicular cancer	0.00167	0.00261	CcSEcCtD
Fosamprenavir—Fatigue—Etoposide—testicular cancer	0.00166	0.00261	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—testicular cancer	0.00165	0.00258	CcSEcCtD
Fosamprenavir—Haemoglobin—Methotrexate—testicular cancer	0.00164	0.00256	CcSEcCtD
Fosamprenavir—Haemorrhage—Methotrexate—testicular cancer	0.00163	0.00255	CcSEcCtD
Fosamprenavir—Dizziness—Ifosfamide—testicular cancer	0.00162	0.00253	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Methotrexate—testicular cancer	0.00161	0.00252	CcSEcCtD
Fosamprenavir—Urethral disorder—Methotrexate—testicular cancer	0.0016	0.0025	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—testicular cancer	0.00159	0.00249	CcSEcCtD
Fosamprenavir—Nausea—Dactinomycin—testicular cancer	0.00158	0.00248	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Etoposide—testicular cancer	0.00158	0.00247	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00156	0.00244	CcSEcCtD
Fosamprenavir—Vomiting—Ifosfamide—testicular cancer	0.00155	0.00244	CcSEcCtD
Fosamprenavir—Hypersensitivity—Cisplatin—testicular cancer	0.00155	0.00243	CcSEcCtD
Fosamprenavir—Rash—Ifosfamide—testicular cancer	0.00154	0.00242	CcSEcCtD
Fosamprenavir—Dermatitis—Ifosfamide—testicular cancer	0.00154	0.00241	CcSEcCtD
Fosamprenavir—Erythema multiforme—Methotrexate—testicular cancer	0.00154	0.00241	CcSEcCtD
Fosamprenavir—Haemoglobin—Epirubicin—testicular cancer	0.00153	0.0024	CcSEcCtD
Fosamprenavir—Abdominal pain—Etoposide—testicular cancer	0.00153	0.00239	CcSEcCtD
Fosamprenavir—Body temperature increased—Etoposide—testicular cancer	0.00153	0.00239	CcSEcCtD
Fosamprenavir—Haemorrhage—Epirubicin—testicular cancer	0.00152	0.00239	CcSEcCtD
Fosamprenavir—Asthenia—Cisplatin—testicular cancer	0.00151	0.00237	CcSEcCtD
Fosamprenavir—Cardiac disorder—Methotrexate—testicular cancer	0.00151	0.00237	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Epirubicin—testicular cancer	0.0015	0.00236	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Epirubicin—testicular cancer	0.0015	0.00235	CcSEcCtD
Fosamprenavir—Urethral disorder—Epirubicin—testicular cancer	0.00149	0.00234	CcSEcCtD
Fosamprenavir—Immune system disorder—Methotrexate—testicular cancer	0.00147	0.0023	CcSEcCtD
Fosamprenavir—Nausea—Ifosfamide—testicular cancer	0.00145	0.00228	CcSEcCtD
Fosamprenavir—Diarrhoea—Cisplatin—testicular cancer	0.00144	0.00226	CcSEcCtD
Fosamprenavir—Erythema multiforme—Epirubicin—testicular cancer	0.00144	0.00226	CcSEcCtD
Fosamprenavir—Hypersensitivity—Etoposide—testicular cancer	0.00142	0.00223	CcSEcCtD
Fosamprenavir—Malnutrition—Methotrexate—testicular cancer	0.00142	0.00222	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—testicular cancer	0.00142	0.00222	CcSEcCtD
Fosamprenavir—Cardiac disorder—Epirubicin—testicular cancer	0.00141	0.00222	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—testicular cancer	0.00141	0.00221	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—testicular cancer	0.00139	0.00218	CcSEcCtD
Fosamprenavir—Asthenia—Etoposide—testicular cancer	0.00139	0.00217	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—testicular cancer	0.00139	0.00217	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—testicular cancer	0.00138	0.00217	CcSEcCtD
Fosamprenavir—Immune system disorder—Epirubicin—testicular cancer	0.00138	0.00216	CcSEcCtD
Fosamprenavir—Pruritus—Etoposide—testicular cancer	0.00137	0.00214	CcSEcCtD
Fosamprenavir—Vomiting—Cisplatin—testicular cancer	0.00134	0.0021	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—testicular cancer	0.00133	0.00209	CcSEcCtD
Fosamprenavir—Rash—Cisplatin—testicular cancer	0.00133	0.00208	CcSEcCtD
Fosamprenavir—Dermatitis—Cisplatin—testicular cancer	0.00133	0.00208	CcSEcCtD
Fosamprenavir—Malnutrition—Epirubicin—testicular cancer	0.00133	0.00208	CcSEcCtD
Fosamprenavir—Diarrhoea—Etoposide—testicular cancer	0.00132	0.00207	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—testicular cancer	0.00131	0.00205	CcSEcCtD
Fosamprenavir—Flatulence—Epirubicin—testicular cancer	0.00131	0.00205	CcSEcCtD
Fosamprenavir—Dizziness—Etoposide—testicular cancer	0.00128	0.002	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—testicular cancer	0.00127	0.002	CcSEcCtD
Fosamprenavir—Nausea—Cisplatin—testicular cancer	0.00125	0.00196	CcSEcCtD
Fosamprenavir—Vomiting—Etoposide—testicular cancer	0.00123	0.00192	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—testicular cancer	0.00123	0.00192	CcSEcCtD
Fosamprenavir—Rash—Etoposide—testicular cancer	0.00122	0.00191	CcSEcCtD
Fosamprenavir—Dermatitis—Etoposide—testicular cancer	0.00122	0.00191	CcSEcCtD
Fosamprenavir—Headache—Etoposide—testicular cancer	0.00121	0.0019	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—testicular cancer	0.00121	0.0019	CcSEcCtD
Fosamprenavir—Myalgia—Methotrexate—testicular cancer	0.00121	0.00189	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.0012	0.00188	CcSEcCtD
Fosamprenavir—Nausea—Etoposide—testicular cancer	0.00115	0.0018	CcSEcCtD
Fosamprenavir—Nervous system disorder—Methotrexate—testicular cancer	0.00113	0.00178	CcSEcCtD
Fosamprenavir—Myalgia—Epirubicin—testicular cancer	0.00113	0.00177	CcSEcCtD
Fosamprenavir—Skin disorder—Methotrexate—testicular cancer	0.00112	0.00176	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00112	0.00176	CcSEcCtD
Fosamprenavir—Anorexia—Methotrexate—testicular cancer	0.0011	0.00173	CcSEcCtD
Fosamprenavir—Nervous system disorder—Epirubicin—testicular cancer	0.00106	0.00166	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00105	0.00165	CcSEcCtD
Fosamprenavir—Skin disorder—Epirubicin—testicular cancer	0.00105	0.00165	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—testicular cancer	0.00104	0.00164	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00104	0.00163	CcSEcCtD
Fosamprenavir—Anorexia—Epirubicin—testicular cancer	0.00103	0.00162	CcSEcCtD
Fosamprenavir—Decreased appetite—Methotrexate—testicular cancer	0.00101	0.00158	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000998	0.00157	CcSEcCtD
Fosamprenavir—Fatigue—Methotrexate—testicular cancer	0.000997	0.00156	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000986	0.00155	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—testicular cancer	0.000982	0.00154	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—testicular cancer	0.000973	0.00152	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—testicular cancer	0.000955	0.0015	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Methotrexate—testicular cancer	0.000946	0.00148	CcSEcCtD
Fosamprenavir—Decreased appetite—Epirubicin—testicular cancer	0.000941	0.00147	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000934	0.00146	CcSEcCtD
Fosamprenavir—Fatigue—Epirubicin—testicular cancer	0.000933	0.00146	CcSEcCtD
Fosamprenavir—Abdominal pain—Methotrexate—testicular cancer	0.000914	0.00143	CcSEcCtD
Fosamprenavir—Body temperature increased—Methotrexate—testicular cancer	0.000914	0.00143	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000912	0.00143	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Epirubicin—testicular cancer	0.000885	0.00139	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—testicular cancer	0.00087	0.00136	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000865	0.00136	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—testicular cancer	0.000863	0.00135	CcSEcCtD
Fosamprenavir—Body temperature increased—Epirubicin—testicular cancer	0.000856	0.00134	CcSEcCtD
Fosamprenavir—Abdominal pain—Epirubicin—testicular cancer	0.000856	0.00134	CcSEcCtD
Fosamprenavir—Hypersensitivity—Methotrexate—testicular cancer	0.000852	0.00134	CcSEcCtD
Fosamprenavir—Asthenia—Methotrexate—testicular cancer	0.00083	0.0013	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000819	0.00128	CcSEcCtD
Fosamprenavir—Pruritus—Methotrexate—testicular cancer	0.000818	0.00128	CcSEcCtD
Fosamprenavir—Hypersensitivity—Epirubicin—testicular cancer	0.000797	0.00125	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—testicular cancer	0.000792	0.00124	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—testicular cancer	0.000792	0.00124	CcSEcCtD
Fosamprenavir—Diarrhoea—Methotrexate—testicular cancer	0.000791	0.00124	CcSEcCtD
Fosamprenavir—Asthenia—Epirubicin—testicular cancer	0.000776	0.00122	CcSEcCtD
Fosamprenavir—Pruritus—Epirubicin—testicular cancer	0.000766	0.0012	CcSEcCtD
Fosamprenavir—Dizziness—Methotrexate—testicular cancer	0.000765	0.0012	CcSEcCtD
Fosamprenavir—Diarrhoea—Epirubicin—testicular cancer	0.00074	0.00116	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—testicular cancer	0.000738	0.00116	CcSEcCtD
Fosamprenavir—Vomiting—Methotrexate—testicular cancer	0.000735	0.00115	CcSEcCtD
Fosamprenavir—Rash—Methotrexate—testicular cancer	0.000729	0.00114	CcSEcCtD
Fosamprenavir—Dermatitis—Methotrexate—testicular cancer	0.000728	0.00114	CcSEcCtD
Fosamprenavir—Headache—Methotrexate—testicular cancer	0.000724	0.00114	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—testicular cancer	0.000718	0.00113	CcSEcCtD
Fosamprenavir—Dizziness—Epirubicin—testicular cancer	0.000716	0.00112	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—testicular cancer	0.000708	0.00111	CcSEcCtD
Fosamprenavir—Vomiting—Epirubicin—testicular cancer	0.000688	0.00108	CcSEcCtD
Fosamprenavir—Nausea—Methotrexate—testicular cancer	0.000687	0.00108	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—testicular cancer	0.000685	0.00107	CcSEcCtD
Fosamprenavir—Rash—Epirubicin—testicular cancer	0.000682	0.00107	CcSEcCtD
Fosamprenavir—Dermatitis—Epirubicin—testicular cancer	0.000682	0.00107	CcSEcCtD
Fosamprenavir—Headache—Epirubicin—testicular cancer	0.000678	0.00106	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—testicular cancer	0.000662	0.00104	CcSEcCtD
Fosamprenavir—Nausea—Epirubicin—testicular cancer	0.000643	0.00101	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—testicular cancer	0.000637	0.000998	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—testicular cancer	0.000631	0.00099	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—testicular cancer	0.000631	0.000989	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—testicular cancer	0.000627	0.000983	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—testicular cancer	0.000595	0.000932	CcSEcCtD
